Journal of Applied Physiology AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 92: 2169-2176, 2002. First published January 11, 2002; doi:10.1152/japplphysiol.00927.2001
8750-7587/02 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
92/5/2169    most recent
00927.2001v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (28)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freedman, S. D.
Right arrow Articles by Alvarez, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freedman, S. D.
Right arrow Articles by Alvarez, J. G.
Vol. 92, Issue 5, 2169-2176, May 2002

Characterization of LPS-induced lung inflammation in cftrminus /minus mice and the effect of docosahexaenoic acid

Steven D. Freedman1, Deborah Weinstein1, Paola G. Blanco1, Pedro Martinez-Clark1, Serge Urman1, Munir Zaman1, Jason D. Morrow2, and Juan G. Alvarez3

Departments of 1 Medicine and 3 Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215; and 2 Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The mechanism by which Pseudomonas causes excessive inflammation in the cystic fibrosis lung is unclear. We have reported that arachidonic acid is increased and docosahexaenoic acid (DHA) decreased in lung, pancreas, and ileum from cftr-/- mice. Oral DHA corrected this defect and reversed the pathology. To determine which mediators regulate inflammation in lungs from cftr-/- mice and whether inhibition occurs with DHA, cftr-/- and wild-type (WT) mice were exposed to aerosolized Pseudomonas lipopolysaccharide (LPS). After 2 days of LPS, tumor necrosis factor-alpha (TNF-alpha ), macrophage inflammatory protein-2, and KC levels in bronchoalveolar lavage fluid were increased in cftr-/- compared with WT mice and not suppressed by pretreatment with oral DHA. Neutrophil levels were not different between cftr-/- and WT mice. After 3 days of aerosolized LPS, neutrophil concentration, TNF-alpha , and the eicosanoids 6-keto-PGF1alpha , PGF2alpha , PGE2, and thromboxane B2 were all increased in bronchoalveolar lavage fluid from cftr-/- mice compared with WT controls. Oral DHA had no significant effect on TNF-alpha levels in cftr-/- mice. In contrast, neutrophils and eicosanoids were decreased in cftr-/- but not in WT mice treated with DHA, indicating that the effects of DHA on these inflammatory parameters may be related to correction of the membrane lipid defect.

cystic fibrosis; cytokines; neutrophils; Pseudomonas


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

CYSTIC FIBROSIS (CF) IS AN autosomal recessive disorder caused by mutations of the gene encoding the CF transmembrane conductance regulator (CFTR) (23). Patients with CF express a typical phenotype characterized by pancreatic insufficiency, ileal hypertrophy, and recurrent pulmonary infections that ultimately lead to pulmonary failure and death. Pulmonary disease in CF is characterized by excessive inflammation in response to infection by Pseudomonas aeruginosa. It has been recently reported that, in the absence of detectable lung infection, the bronchoalveolar lavage (BAL) fluid of CF patients contains increased levels of proinflammatory cytokines and neutrophils (2, 18, 20). In addition, interleukin (IL)-8 levels in BAL fluid from children with CF are significantly higher than those in non-CF children with bacterial infection of the lower airways (21). Furthermore, basal secretion of IL-6 and IL-8 was higher in human CF bronchial gland cells than in human gland cells obtained from normal individuals (16, 26). These data suggest that CFTR mutations may lead to an excessive inflammatory response in the lung.

The mechanism responsible for this enhanced inflammatory response has been difficult to study in vivo because cftr-/- mice [University of North Carolina (UNC) knockouts] show little spontaneous lung inflammation. To circumvent this problem, a model has been established whereby instillation of agarose beads coated with Pseudomonas into the lungs of S489X cftr-/- mice has been shown to result in increased inflammation and mortality compared with that observed in wild-type (WT) mice (13, 14). However, in those studies, the mortality rate was significant in both control and cftr-/- mice. This could be due, at least in part, to airway obstruction after instillation of the agarose beads.

Our laboratory (11) has recently reported the presence of a membrane lipid defect in lung, pancreas, and ileum from cftr-/- mice characterized by an increase in phospholipid-bound arachidonic acid and a decrease in phospholipid-bound docosahexaenoic acid (DHA). Correction of this fatty acid defect with high doses of oral DHA led to reversal of the pathological manifestations of CF in pancreas and ileum. However, cftr-/- mice do not express spontaneous pulmonary disease. Therefore, an animal model was established whereby mice were exposed to aerosolized Pseudomonas lipopolysaccharide (LPS) once a day for 3 days to mimic persistent infection in CF. This demonstrated a twofold increase in neutrophil concentration in BAL fluid from cftr-/- mice compared with that observed in WT mice (11).

The objective of this study was to determine which specific proinflammatory mediators may be responsible for the enhanced inflammatory response observed in lungs from cftr-/- mice after exposure to Pseudomonas LPS and whether oral DHA suppresses this enhanced inflammatory response. Using this model, we demonstrate that there is an increased neutrophil infiltration in lungs from cftr-/- mice compared with WT mice in response to Pseudomonas LPS and that this neutrophil infiltration is preceded by an increase in the production of tumor necrosis factor-alpha (TNF-alpha ), macrophage inflammatory protein-2 (MIP-2), and KC. In addition, the levels of the eicosanoids PGF1alpha (6-keto-PGF1alpha ), PGF2alpha , PGE2, and thromboxane B2 (TxB2) were all increased in BAL fluid from cftr-/- mice compared with those in WT controls. Oral administration of DHA resulted in a selective decrease in these eicosanoids in cftr-/- mice that was not observed in WT mice.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Breeding of cftr-/- mice and oral administration of DHA. Experiments were approved by the Beth Israel Deaconess Medical Center Animal Care Committee. A breeding colony was established with UNC heterozygous cftr-/- exon 10 knockout mice (Jackson Laboratories, Bar Harbor, ME). Tail clip samples of 14-day-old mice were processed for analysis of genotype (28). Both WT (C57 as well as UNC cftr+/+ mice) and cftr-/- mice were weaned at 23 days of age. After weaning, age-matched WT and cftr-/- mice were placed on water and Peptamen (Nestle Clinical Nutrition, Deerfield, IL) ad libitum until 30 days of age and then continued for 7 days with Peptamen or 40 mg/day of DHA (Sigma Chemical, St. Louis, MO) prepared as a stable emulsion in Peptamen. The volume of Peptamen administered was measured on a daily basis with specific feeders.

Analysis of lung inflammation. Weight-matched WT and cftr-/- mice, with and without pretreatment with oral DHA, were given a single dose of aerosolized Pseudomonas LPS (10 mg/15 g body wt, unless indicated) over 15 min once a day for up to 3 days. Pseudomonas LPS (Sigma Chemical) was sonicated in saline and administered at 20 lb./in.2 with a nebulizer connected to a compressed air tank, which was connected to a large plastic container with vent holes into which the animals were placed. It should be noted that WT mice generally weigh more than age-matched cftr-/- mice, and thus weight-matched animals were used in experiments. All animals were between 30 and 37 days of age.

Mice were killed 3, 6, or 10 h after receiving their last dose of Pseudomonas LPS. BAL was done by using four aliquots of 1 ml of sterile saline containing 1× protease inhibitor cocktail (Sigma Chemical). This was injected through polyethylene tubing placed into the upper airway after an incision into the trachea. Each aliquot of saline was introduced and removed slowly over 1 min to minimize trauma and hence red blood cell contamination. One-milliliter aliquots provided optimal lavage of the lungs without significant trauma.

Neutrophils were obtained after centrifugation of BAL fluid at room temperature for 8 min at 800 g. The resulting pellet was resuspended in 50 µl of PBS, and neutrophil concentration was determined by phase-contrast microscopy. Neutrophils were positively identified by myeloperoxidase staining and microscopic analysis by using tetramethylbenzidine-H2O2 as the peroxidase substrate. The remaining BAL fluid was centrifuged at 14,000 g for 10 min, and the supernatant was analyzed for cytokine and chemokine levels. For leukotriene B4 (LTB4) analysis, BAL fluid was centrifuged at 1,000 g for 10 min, then concentrated under reduced pressure (SpeedVac), resuspended in 0.25 ml of 50% aqueous methanol, and analyzed by enzyme immunoassay (Cayman Chemical, Ann Arbor, MI) (19). TNF-alpha , MIP-2, KC, and IL-1beta levels in BAL fluid were determined with commercially available EIA kits (R&D Systems, Minneapolis, MN) with lower limits of detection of 10, 5, 15, and 5 pg/ml, respectively. PGF1alpha (6-keto-PGF1alpha ), PGF2alpha , PGE2, and TxB2 were quantified by using stable isotope dilution methodology employing gas chromatography-negative ion chemical ionization mass spectrometry (7).

Statistical analysis. The differences between the means were evaluated by using Student's t-test comparing two conditions and ANOVA for comparing three or more variables.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Selection of Pseudomonas LPS dose. To determine the optimum dose of LPS, aerosolized Pseudomonas LPS was administered at different doses to WT mice, and, after 3 h, neutrophil, TNF-alpha , and KC levels in BAL fluid were measured (Fig. 1). Neutrophils, TNF-alpha , and KC were undetectable in BAL fluid of mice treated with LPS-free saline. After administration of up to 5 mg LPS/15 g body wt, neutrophil concentration and TNF-alpha in BAL fluid increased linearly (P < 0.05 comparing 0, 1, and 5 mg LPS by ANOVA), with no further significant increase at 10 mg LPS/15 g body wt. KC levels were also increased in BAL fluid in a dose-dependent manner, with the exception that the increase was statistically different (P < 0.05) among all values examined from 0 to 10 mg LPS/15 g body wt. Because 10 mg LPS/15 g body wt resulted in maximal neutrophil levels, this dose was used for subsequent experiments. Also, because there was no significant difference in the results obtained from UNC cftr+/+ mice compared with C57 WT mice either for a single dose of aerosolized LPS or after 2 or 3 days of repeated daily administration of aerosolized Pseudomonas LPS (data not shown), the latter were used for subsequent experiments.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 1.   Lipopolysaccharide (LPS) dose-response curve. Wild-type (WT) mice were exposed to different doses of aerosolized Pseudomonas LPS and killed 3 h later, and bronchoalveolar lavage (BAL) was performed. A: neutrophil concentration in BAL fluid. B: tumor necrosis factor-alpha (TNF-alpha ) and KC levels. Results are means ± SE from 3 separate experiments. [LPS], LPS concentration.

Repeated administration of Pseudomonas LPS. The effects of repeated administration of aerosolized Pseudomonas LPS on cytokine, chemokine, and neutrophil levels were examined in WT mice. TNF-alpha , MIP-2, and KC levels in BAL fluid peaked on day 1, 3 h after the initial inhalation (Fig. 2). On the next 2 days, levels of these inflammatory mediators also peaked 3 h after LPS inhalation. However, these levels were two- to threefold lower than peak levels observed on day 1. IL-1beta increased after 2 days of aerosolized LPS exposure to only twice its level on day 1 with no further significant increase. In contrast, neutrophil concentration in BAL fluid increased slowly on day 1 relative to cytokine and chemokine levels, exhibiting a twofold increase from day 1 to day 2. Neutrophil concentration in BAL fluid remained relatively constant at these levels on days 2 and 3, with the occurrence of small spikes that coincided with the increase in cytokine levels. Neutrophils were the predominant inflammatory cells with <3% lymphocytes and macrophages identifiable by light microscopy (Fig. 3A). Neutrophils were present throughout the air spaces, including both bronchi and alveoli.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Time course production of cytokines and chemokines in BAL fluid after Pseudomonas LPS exposure. Weight-matched WT mice were exposed to aerosolized Pseudomonas LPS once a day for up to 3 days. Animals were killed 3, 6, or 10 h after the last dose of LPS, and BAL was performed. A: chemokine and neutrophil concentration in BAL fluid. B: TNF-alpha and interleukin (IL)-1beta levels. Values are means ± SE from at least 3 separate experiments. MIP-2, macrophage inflammatory protein.



View larger version (137K):
[in this window]
[in a new window]
 
Fig. 3.   Light micrographs of the lungs from cftr-/- and WT mice exposed to aerosolized Pseudomonas LPS for 3 days. Tissue was fixed in 10% buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin. Representative micrographs of lung tissue from WT mice (A) and cftr-/- mice (B) are shown (×200 magnification). Arrows indicate neutrophils within the alveolar space. Arrowheads indicate neutrophils within bronchi.

Comparison of cytokine, chemokine, and neutrophil levels in cftr-/- and WT mice after Pseudomonas LPS-induced inflammation. We then investigated whether levels of these inflammatory mediators were different in cftr-/- compared with WT mice. TNF-alpha , MIP-2, and KC levels in BAL fluid on day 2 were significantly higher (P < 0.05) in cftr-/- mice than in WT mice (Fig. 4). IL-1beta levels were low, with no significant differences between cftr-/- and WT mice. Although a similar trend was observed after 3 days of aerosolized Pseudomonas LPS, only TNF-alpha demonstrated a statistically significant difference (P < 0.05) in cftr-/- compared with WT mice (Fig. 5).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Cytokine and chemokine levels in cftr-/- and WT mice exposed to aerosolized Pseudomonas LPS for 2 days. Weight-matched mice fed either Peptamen (cftr-/- and WT) or Peptamen containing 40 mg of docosahexaenoic acid (DHA) for 7 days (cftr-/- + DHA and WT + DHA) were exposed to aerosolized Pseudomonas LPS once a day for 2 days. Mice were killed 3 h after the last dose of LPS, and BAL was performed. Total levels of TNF-alpha , IL-1beta , KC, and MIP-2 in BAL fluid are shown for each group. Values are means ± SE and correspond to at least 7 different experiments per group. * Significant difference, P < 0.05.



View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   Cytokine and chemokine levels in cftr-/- and WT mice exposed to aerosolized Pseudomonas LPS for 3 days. The same conditions were utilized as per Fig. 4, except that WT and cftr-/- mice were exposed to LPS for 3 days. * Significant difference, P < 0.05.

Eicosanoid levels in cftr-/- and WT mice after Pseudomonas LPS-induced inflammation. Eicosanoids were also examined in this model after administration of aerosolized LPS for 3 days. 6-keto-PGF1alpha , PGF2alpha , PGE2, and TxB2 levels were significantly higher in BAL fluid from cftr-/- compared with WT mice (P < 0.05) (Fig. 6A). No significant differences in LTB4 levels were observed between cftr-/- and WT mice (Fig. 6B).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 6.   Eicosanoid levels in BAL fluid from cftr-/- and WT mice treated with aerosolized Pseudomonas LPS. Weight-matched cftr-/- and WT mice fed either Peptamen or Peptamen containing 40 mg of DHA were exposed to aerosolized Pseudomonas LPS once each day for 3 days. Mice were killed 3 h after the last dose of LPS, and BAL was performed. A: 6-keto-PGF1alpha , PGF2alpha , PGE2, and thromboxane B2 (TxB2) levels were examined. B: leukotriene B4 (LTB4) levels were measured. Values are means ± SE from at least 3 separate experiments. * Significant difference, P < 0.05.

Effect of DHA pretreatment on Pseudomonas LPS-induced inflammation. Pretreatment of either cftr-/- or WT mice with oral DHA had no effect on IL-1beta after either 2 or 3 days of aerosolized Pseudomonas LPS exposure (Figs. 4 and 5). Similarly, DHA administration to WT or cftr-/- mice did not cause significant changes in MIP-2 or KC levels in BAL fluid after 2 and 3 days of exposure to aerosolized LPS. WT mice treated with oral DHA demonstrated a statistically significant decrease in TNF-alpha levels (P < 0.05) after 2 and 3 days of Pseudomonas LPS exposure compared with untreated WT mice (Figs. 4 and 5). Although similar trends in TNF-alpha levels were observed after DHA administration to cftr-/- mice, these changes were not statistically significant.

Eicosanoids were also examined under these conditions. Pretreatment of cftr-/- mice with oral DHA resulted in a significant decrease in 6-keto-PGF1alpha , PGF2alpha , PGE2, and TxB2 levels in BAL fluid (P < 0.05) (Fig. 6). These levels were similar to those observed in WT animals either treated or not treated with DHA. LTB4 levels were not significantly altered by DHA.

Cytokine production and neutrophil concentration in BAL fluid. To determine the relationship between cytokine levels and neutrophil infiltration in cftr-/- and WT mice, neutrophil concentration in BAL fluid was determined at different times after LPS exposure. Neutrophil concentration in BAL fluid was significantly increased in cftr-/- mice compared with WT controls after exposure to aerosolized LPS for 3 days (P = 0.004) (Fig. 7). This is seen in the representative micrographs shown in Fig. 3. This difference in neutrophil concentration between WT and cftr-/- mice was not observed on day 2. Pretreatment of cftr-/- mice with oral DHA suppressed the increase in neutrophil concentration observed on day 3 to levels found in WT mice but had no effect on neutrophil concentration on day 2. Pretreatment of WT mice with DHA did not have any significant effect on neutrophil concentration in BAL fluid from WT mice on either day 2 or 3.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 7.   Neutrophil concentration in BAL fluid from cftr-/- mice after 2- and 3-day exposure to aerosolized Pseudomonas LPS. Weight-matched cftr-/- and WT mice fed either Peptamen or Peptamen containing 40 mg DHA were exposed to aerosolized Pseudomonas LPS once each day for either 2 or 3 days. Animals were killed 3 h after last dose of LPS, and BAL was performed. Values are mean neutrophil concentration (million/ml) ± SE from at least 8 experiments per group. Significant difference, * P < 0.01 and ** P < 0.005.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Because chronic exposure to Pseudomonas plays a major role in the pathogenesis of CF-induced lung disease, we have examined the effects of repeated aerosolized Pseudomonas LPS exposure on the genesis of lung inflammation in cftr-/- mice. This model has the advantage that the mortality rate is negligible in contrast to the 23% mortality rate observed in WT mice after intratracheal instillation of Pseudomonas-coated agarose beads (14). Using a different approach, Thomas et al. (26a) have shown that intravenous administration of LPS leads to a qualitative increase in the number of neutrophils in the lung parenchyma of mice with the G551D mutation in CFTR compared with WT control mice, although the air spaces were devoid of inflammatory cells. Davidson et al. (8) examined the effects of aerosolized Staphylococcus aureus and Burkholderia cepacia given daily in low doses for up to 1 mo to cftrm1HGU mice. In these animals, which display a milder phenotype, a predominantly lymphoid infiltrate was present in the lungs and was associated with goblet cell hyperplasia and mucus retention. No mortality was observed. However, the pneumonia observed in CF patients is characterized by a predominantly neutrophilic infiltrate, and thus this model is not representative of lung disease in CF patients. Our present model, which results in a predominantly neutrophilic infiltrate, is more representative of lung disease in humans, although alveoli tend to be less involved in humans with CF. However, both our model as well as the Pseudomonas-coated agarose bead model result in infiltration of inflammatory cells in the upper airways as well as the alveoli (13). Although important information can be learned from LPS-stimulated inflammation, Pseudomonas factors in addition to LPS are also likely to influence the host response and progression to chronic infection in human CF, such as secreted toxins, proteases, alginate, and other virulence factors.

The fact that an increase in neutrophil concentration in BAL fluid from cftr-/- mice, compared with WT controls, was observed after 3 but not after 2 days of aerosolized Pseudomonas LPS exposure allowed us to attempt to discriminate which inflammatory mediators may be responsible for this excessive inflammatory response in cftr-/- mice. In cftr-/- mice, the increase in neutrophils was preceded by a rise in TNF-alpha levels, which were significantly increased above WT values after 2 and 3 days of aerosolized Pseudomonas LPS. Although KC and MIP-2 levels on days 2 and 3 were higher in cftr-/- mice than in WT, statistical significance was reached only on day 2. These data suggest that TNF-alpha , MIP-2, and KC may be important mediators of the enhanced inflammatory response observed in lungs from cftr-/- mice. This is in agreement with the results obtained after intratracheal instillation of Pseudomonas-coated agarose beads, where these were the only inflammatory mediators that demonstrated a statistically significant increase compared with WT controls (14). However, in that model, neutrophil levels were minimally increased in cftr-/- compared with WT mice, whereas LTB4 and IL-1beta levels were markedly increased, although these differences were not statistically significant. In our model, LTB4 levels were not different between cftr-/- and WT mice under these conditions. Pretreatment of cftr-/- mice with oral DHA did not significantly decrease TNF-alpha , MIP-2, or KC levels. Similarly, DHA administration did not significantly alter MIP-2 and KC levels in WT mice, although TNF-alpha levels were statistically decreased. Taken together, these data indicate that, under the conditions utilized, DHA treatment does not suppress these proinflammatory cytokines in the lungs of cftr-/- mice.

Eicosanoids were also examined to determine their role in this inflammatory process. 6-Keto-PGF1alpha , PGF2alpha , PGE2, and TxB2 levels were elevated in cftr-/- mice compared with WT control animals, suggesting that these arachidonic acid metabolites may also play an important role in the initial stages of the enhanced lung inflammatory response observed in cftr-/- mice. This is in agreement with data from other groups demonstrating an increase in eicosanoids in BAL fluid (19), saliva (22a), and urine (24a) from CF patients. The fact that pretreatment of cftr-/- mice, but not WT mice, with oral DHA resulted in suppression of these eicosanoids suggests that DHA may be reversing a specific abnormality related to CFTR dysfunction, perhaps related to the abnormality in fatty acid metabolism. Specifically, the elevated levels of phospholipid-bound arachidonic acid may be directly responsible for the increased production of eicosanoids. Administration of oral DHA, by competing for incorporation at the sn-2 position in membrane phospholipids, decreases arachidonic acid levels, thereby lowering the production of eicosanoids. However, the lowering of eicosanoids is not a generalized phenomena, because LTB4 levels were not affected by oral administration of DHA in this animal model. Because virtually all cells can synthesize eicosanoids, it is difficult to identify which cell type(s) is responsible for the increased levels produced in the lungs of cftr-/- mice. Outside of LTB4, there are few studies examining whether other eicosanoids participate in leukocyte recruitment. Of the four eicosanoids found to be increased in this model of aerosolized LPS-induced lung inflammation and specifically suppressed by oral DHA, only PGF2alpha has been shown to have potent polymorphonuclear neutrophil chemotactic activity (1, 15, 24). This was not observed with PGE2 (1), and 6-keto-PGF1alpha and TxB2 have not been directly tested. These data suggest that the decrease in neutrophil concentration in BAL fluid after pretreatment of cftr-/- mice with DHA may be, in part, mediated through a decrease in PGF2alpha -induced neutrophil recruitment. Further experiments that use specific inhibitors of PGF2alpha may clarify the role of this molecule.

There is increasing evidence that a defect in CFTR function leads to an exaggerated inflammatory host response in both respiratory epithelial cells, as well as in lung resident macrophages. This appears to be a constitutive abnormality, because CF bronchial submucosal glands cultured from CF patients demonstrate an increase in basal IL-6 and IL-8 levels compared with non-CF control cells (16, 26). This increase in IL-8 levels can be explained by significant amounts of constitutively activated nuclear factor-kappa B (NF-kappa B) in these CF cell lines (9). In addition, human CF bronchial gland cells display a lack of cytosolic factor I-kappa Balpha , also resulting in an upregulation of IL-8 production compared with non-CF disease bronchial gland cells (25). These results were confirmed in cultured human CF bronchial gland cells in which a lack of cytosolic I-kappa Balpha and high levels of constitutively activated NF-kappa B, associated with an upregulation of IL-8 production, were found compared with non-CF disease bronchial gland cells. In addition to this increase in these proinflammatory mediators, IL-10 levels have been reported to be markedly decreased both in BAL fluid (6) and in isolated bronchial epithelial cells from CF patients (5). Furthermore, the notion that CFTR mutations predispose to enhanced lung inflammation is supported by the fact that BAL fluid from CF infants, before demonstrable colonization or infection occurs, contains higher concentrations of neutrophils and IL-8 compared with BAL fluid from disease control infants (2, 18).

In an effort to determine whether inflammatory cells in addition to respiratory epithelial cells are involved in the genesis of this altered inflammatory response, macrophages from CF patients, both differentiated in vitro from monocytes (22) and from BAL fluid (6, 18), have been shown to secrete increased levels of IL-8 as well as TNF-alpha . This is in agreement with the fact that monocytes contain low levels of CFTR based on RT-PCR and southern analysis (27). In the present model, it should be emphasized that respiratory epithelial cells, in contrast to the macrophage, minimally respond to bacterial LPS with no stimulation of IL-8 secretion (10). Therefore, the initial inflammatory response to LPS is generated by the lung macrophage. Production of TNF-alpha and other cytokines by macrophages after exposure to Pseudomonas LPS may lead to secondary production of cytokines by respiratory epithelial cells and to an amplification of the inflammatory response. Whether the increase in TNF-alpha , MIP-2, and KC levels in BAL fluid from cftr-/- mice of observed exposure to Pseudomonas LPS is of macrophage origin, from the respiratory epithelium, or a combination cannot be ascertained in this model.

An alternative mechanism that would explain our findings of an exaggerated inflammatory response in CF is a defect in the development of tolerance to repeated LPS exposure. Endotoxin tolerance was first described by Beeson (3), who observed a decrease in febrile response after repeated injection of rabbits with endotoxin, and appears to be a protective mechanism to prevent uncontrolled immunological activation in the host after septicemia that could lead to continuous production of proinflammatory cytokines, such as TNF-alpha , and to severe vascular collapse (29). The principal cells responsible for the development of this tolerance effect are monocytes and macrophages (12). This effect is not secondary to a decrease in CD14, the LPS receptor on the cell surface of these cells, but perhaps is due to a formation of inactive NF-kappa B complexes consisting of p50 homodimers (4). Alternatively, tolerance may result from the downregulation of IL-12 secretion observed after chronic exposure of human monocytes to LPS in culture (17). Taken together, these data would be consistent with the notion that the development of endotoxin tolerance is defective in CF and perhaps DHA modulates this tolerance mechanism. Further experiments are required to determine the validity of this hypothesis in cftr-/- mice.

Our previous data indicate that a membrane lipid imbalance is present in ileum, pancreas, and lung from cftr-/- mice, characterized by a selective increase in phospholipid-bound arachidonic acid and a decrease in phospholipid-bound DHA (11). Treatment of these mice with oral DHA resulted in correction of the lipid abnormality as well as reversal of the pathology in pancreas and ileum. Although the effects of DHA on suppression of TNF, MIP-2, and KC levels in BAL fluid were similar in both WT and cftr-/- mice exposed to Pseudomonas LPS, the fact that neutrophils and the eicosanoids studied were decreased only in cftr-/- mice but not WT animals suggests that the membrane lipid imbalance observed in lungs from cftr-/- mice may play an important role in the pathogenesis of this enhanced pulmonary inflammation.


    ACKNOWLEDGEMENTS

We thank Dr. Rene Mora from the Department of Medicine at Beth Israel Deaconess Medical Center for help in setting up the Pseudomonas LPS nebulizer apparatus. We also thank Dr. Christopher Karp from the Department of Infectious Diseases at The Johns Hopkins University for critical review of this manuscript.


    FOOTNOTES

This work was supported by the Cystic Fibrosis Foundation (J. G. Alvarez and S. D. Freedman) and by National Institutes of Health Grants GM-15431, DK-48831, and CA-77839 (to J. D. Morrow). J. D. Morrow is also the recipient of a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.

Address for reprint requests and other correspondence: S. D. Freedman, Beth Israel Deaconess Medical Center, Dana 532, 330 Brookline Ave., Boston, MA 02215 (E-mail: sfreedma{at}caregroup.harvard.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

First published January 11, 2002;10.1152/japplphysiol.00927.2001

Received 6 September 2001; accepted in final form 9 January 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Arnould, T, Thibaut-Vercruyssen R, Bouaziz N, Dieu M, Remacle J, and Michiels C. PGF2alpha , a prostanoid released by endothelial cells activated by hypoxia, is a chemoattractant candidate for neutrophil recruitment. Am J Pathol 159: 345-357, 2001.

2.   Balough, K, McCubbin M, Weinberger M, Smits W, Ahrens R, and Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 20: 63-70, 1995.

3.   Beeson, PB. Tolerance to bacterial pyrogens. I. Factors influencing its development. J Exp Med 86: 29-44, 1947.

4.   Bohuslav, J, Kravchenko VV, Parry GC, Erlich JH, Gerondakis S, Mackman N, and Ulevitch RJ. Regulation of an essential innate immune response by the p50 subunit of NF-kappa B. J Clin Invest 102: 1645-1652, 1998.

5.   Bonfield, TL, Konstan MW, and Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 104: 72-78, 1999.

6.   Bonfield, TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, and Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152: 2111-2118, 1995.

7.   Coffey, RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, and Morrow JD. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 94: 657-662, 1997.

8.   Davidson, DJ, Dorin JR, McLachlan G, Ranaldi V, Lamb D, Doherty C, Govan J, and Porteous DJ. Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. Nat Genet 9: 351-357, 1995.

9.   DiMango, E, Ratner AJ, Bryan R, Tabibi S, and Prince A. Activation of NF-kappa B by adherent Psuedomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 101: 2598-2605, 1998.

10.   DiMango, E, Zar HJ, Bryan R, and Prince A. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 96: 2204-2210, 1995.

11.   Freedman, SD, Katz MH, Parker EM, Laposata M, Urman MY, and Alvarez JA. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/- mice. Proc Natl Acad Sci USA 96: 13995-14000, 1999.

12.   Freudenber, MD, and Galanos C. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun 56: 1352-1357, 1988.

13.   Gosselin, D, Stevenson MM, Cowley EA, Griesenbach U, Eidelman DH, Boule M, Tam MF, Kent G, Skamene E, Tsui LC, and Radzioch D. Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa. Am J Respir Crit Care Med 157: 1253-1262, 1998.

14.   Heeckeren, A, Walenga R, Konstan MW, Bonfield T, Davis PB, and Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 100: 2810-2815, 1997.

15.   Hoedemaker, M, Lund LA, and Wagner WC. Influence of arachidonic acid metabolites and steroids on function of bovine polymorphonuclear neutrophils. Am J Vet Res 53: 1534-1539, 1992.

16.   Kammouni, W, Figarella C, Marchand S, and Merten M. Altered cytokine production by cystic fibrosis tracheal gland serous cells. Infect Immun 65: 5176-5183, 1997.

17.   Karp, CL, Wysocka M, Ma X, Marovich M, Factor RE, Nutman T, Armant M, Wahl L, Cuomo P, and Trinchieri G. Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. Eur J Immunol 28: 3128-3136, 1998.

18.   Khan, TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, and Riches DWH Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151: 1075-1082, 1995.

19.   Kostan, MW, Walenga RW, Hillard KA, and Hillard JB. Leukotriene B4 is markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 148: 896-901, 1993.

20.   Muhlebach, M, Stewart P, Leigh M, and Noah T. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 160: 186-191, 1999.

21.   Noah, TL, Black HR, Cheng PW, Wood RE, and Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 175: 638-647, 1997.

22.   Pfeffer, KD, Huecksteadt TP, and Hoidal JR. Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients. Am J Respir Cell Mol Biol 9: 511-519, 1993.

22a.   Rigas, B, Korenberg JR, Merrill WW, and Levine L. Prostaglandins E2 and F2alpha are elevated in saliva of cystic fibrosis patients. Am J Gastroenterol 84: 1408-1412, 1989.

23.   Riordan, JR, Rommens JM, Kerem BS, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073, 1989.

24.   Roch-Arveiller, M, Drouin JY, Puisieux F, and Giroud JP. Direct identification of a chemoattractant by a visual assay. Blood Cells 10: 129-133, 1984.

24a.   Strandvik, B, Svensson E, and Seyberth HW. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 55: 419-425, 1996.

25.   Tabary, O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, and Jacquot J. Genistein inhibits constitutive and inducible NFkB activation and decreases IL-8 production by cystic bronchial gland cells. Am J Pathol 155: 473-481, 1999.

26.   Tabary, O, Zahm JM, Hinnrasky J, Couetil JP, Cornillet P, Guenounou M, Gaillard D, Puchelle E, and Jacquot J. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol 153: 921-930, 1998.

26a.   Thomas, GR, Costelloe EA, Lunn DP, Stacey KJ, Delaney SJ, Passey R, McGlinn EC, McMorran BJ, Ahadizadeh A, Geczy CL, Wainwright BJ, and Hume DA. G551D Cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages. J Immunol 164: 3870-3877, 2000.

27.   Yoshimura, K, Nakamura H, Trapnell BC, Chu CS, Dalemans W, Pavirani A, Lecocq JP, and Crystal RG. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 19: 5417-5423, 1991.

28.   Zeng, W, Lee MG, Yan M, Diaz J, Benjamin I, Marino CR, Kopito R, Freedman S, Cotton C, Muallem S, and Thomas P. Immuno and functional characterization of CFTR in submandibular and pancreatic acinar and duct cells. Am J Physiol Cell Physiol 273: C442-C455, 1997.

29.   Ziegler-Heitbrock, HWL Molecular mechanism to tolerance to lipopolysaccharide. J Inflamm 45: 13-26, 1995.


J APPL PHYSIOL 92(5):2169-2176
8750-7587/02 $5.00 Copyright © 2002 the American Physiological Society



This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
E. M. Bruscia, P.-X. Zhang, E. Ferreira, C. Caputo, J. W. Emerson, D. Tuck, D. S. Krause, and M. E. Egan
Macrophages Directly Contribute to the Exaggerated Inflammatory Response in Cystic Fibrosis Transmembrane Conductance Regulator-/- Mice
Am. J. Respir. Cell Mol. Biol., March 1, 2009; 40(3): 295 - 304.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
T. R. Bartling and M. L. Drumm
Oxidative Stress Causes IL8 Promoter Hyperacetylation in Cystic Fibrosis Airway Cell Models
Am. J. Respir. Cell Mol. Biol., January 1, 2009; 40(1): 58 - 65.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
H. Tiesset, M. Pierre, J.-L. Desseyn, B. Guery, C. Beermann, C. Galabert, F. Gottrand, and M.-O. Husson
Dietary (n-3) Polyunsaturated Fatty Acids Affect the Kinetics of Pro- and Antiinflammatory Responses in Mice with Pseudomonas aeruginosa Lung Infection
J. Nutr., January 1, 2009; 139(1): 82 - 89.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. Andersson, M. R. Al-Turkmani, J. E. Savaille, R. Alturkmani, W. Katrangi, J. E. Cluette-Brown, M. M. Zaman, M. Laposata, and S. D. Freedman
Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism
J. Lipid Res., August 1, 2008; 49(8): 1692 - 1700.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Perez, A. M. van Heeckeren, D. Nichols, S. Gupta, J. F. Eastman, and P. B. Davis
Peroxisome proliferator-activated receptor-{gamma} in cystic fibrosis lung epithelium
Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L303 - L313.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
A. Saadane, S. Masters, J. DiDonato, J. Li, and M. Berger
Parthenolide Inhibits I{kappa}B Kinase, NF-{kappa}B Activation, and Inflammatory Response in Cystic Fibrosis Cells and Mice
Am. J. Respir. Cell Mol. Biol., June 1, 2007; 36(6): 728 - 736.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. M. White, D. Jiang, J. D. Burgess, I. R. Bederman, S. F. Previs, and T. J. Kelley
Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis
Am J Physiol Lung Cell Mol Physiol, February 1, 2007; 292(2): L476 - L486.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
C. Guilbault, Z. Saeed, G. P. Downey, and D. Radzioch
Cystic Fibrosis Mouse Models
Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 1 - 7.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
O. Tabary, H. Corvol, E. Boncoeur, K. Chadelat, C. Fitting, J. M. Cavaillon, A. Clement, and J. Jacquot
Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions
Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L588 - L596.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
P. G. Blanco, M. M. Zaman, O. Junaidi, S. Sheth, R. K. Yantiss, I. A. Nasser, and S. D. Freedman
Induction of colitis in cftr-/- mice results in bile duct injury
Am J Physiol Gastrointest Liver Physiol, August 1, 2004; 287(2): G491 - G496.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. D. Freedman, P. G. Blanco, M. M. Zaman, J. C. Shea, M. Ollero, I. K. Hopper, D. A. Weed, A. Gelrud, M. M. Regan, M. Laposata, et al.
Association of Cystic Fibrosis with Abnormalities in Fatty Acid Metabolism
N. Engl. J. Med., February 5, 2004; 350(6): 560 - 569.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. N. Serhan, S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R.-L. Moussignac
Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals
J. Exp. Med., October 21, 2002; 196(8): 1025 - 1037.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
92/5/2169    most recent
00927.2001v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (28)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freedman, S. D.
Right arrow Articles by Alvarez, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freedman, S. D.
Right arrow Articles by Alvarez, J. G.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online